- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03725046
Impact of an Optimized Communication on the Readmission for Adverse Drug Event (URGEIM)
Evaluation of the Impact of an Optimized Communication Between Hospital and Community on the Readmission at the Emergency Department for an Adverse Drug Event : Randomized Controlled Trial
Emergency departments (EDs) are a crucial element of health care systems as they constitute the interface between hospital and communities. The goals of the ED are to make an initial diagnosis and deliver urgent and critical care 24 hours per day and 365 days a year. Also, many Adverse Drug Events (ADEs) are not identified by emergency physicians. ADEs are injuries resulting from a drug related medical intervention. Their detection, documentation and reporting are essential for adequate medical care and knowledge of risk/benefit profiles of medication throughout their lifecycle. However, a number of studies indicate that in clinical practice the under-reporting of ADEs is a pervasive and widespread problem. The main reasons for under-reporting were difficulty in determining the cause of the ADE, lack of time, poor integration of ADE-reporting systems and uncertainty about reporting procedures. Successful treatment of ADEs depends on the ability of physicians to attribute ADEs to a medication. Some studies have reported that not only pharmacists but also pharmacy student were one of the best health care providers to establish medication history and detected ADEs.
It has also been shown that a clinical pharmacist, within the emergency medical team, can improve the detection of ADE through drug expertise and reliable drug history. This approach has been adopted at Montpellier University Hospital since November 2011. During the initial diagnosis of the ADE, the revision of a drug treatment at risk cannot be carried out in emergency department by the emergency physician. Indeed, the latter intervenes punctually but he is not the patient's referring doctor. Guidance and follow-up of the patient throughout the care journey is the responsibility of the referring physician, sometimes accompanied by the pharmacist. It is therefore very important that a relevant information detected at the hospital can be passed on to the referring health professionals who will review and adapt the treatment. The city-hospital link is essential to guarantee the continuity and the consistence of the care process. When a patient is discharging with the emergency department, the outgoing mail often mentions only the reason for admission, and the information concerning the detection or suspicion of an ADE is not systematically stipulated. However, this information is essential to trigger a process of therapeutic revision (therapeutic modification, therapeutic education, referral to specialized consultations ...) that will prevent the recurrence of the ADE and therefore the readmission to emergency department. To date, the rate of readmission to emergency department after a first visit related to an ADE is between 3.6 and 18.7%.
Our goal is to evaluate the impact at 6 months of a medical-pharmaceutical follow-up and the optimization of the city-hospital link following an admission at emergency department for ADE, on the readmission to emergency department for the same ADE.
This is a single-center randomized, controlled, open-label, two-arm, parallel, "usual information transmission" or "optimized information transmission" study. The duration of a patient's follow-up is 6 months.
Each patient with an occurring ADE detected during emergency department admission could be participating in the study.
Specific management of the experimental group: Sending to the community referring physician by the emergency department an discharge report containing the reason for emergency consultations (report currently made as part of the treatment). Within 72 hours (working hours), the Emergency Clinical Pharmacist contacts the referring physician and the patient's community pharmacist to discuss how to manage the ADE. In parallel, a second report, summary of the ADE (ADE-report), is sent to them. The ADE-report, written and validated by the investigators (emergency physician and clinical pharmacist), includes the type of ADE, the suspected drug(s) and other recommendations: therapeutic modification, referral to specialized consultations (geriatrics ...)
Control group: The emergency department sends to the referring doctor a letter to inform him about the reason of consultations in the emergency department (mail currently realized as part of the care process).
Primary outcome measure: Percentage of patients who had at least one readmission for the same reason in the emergency department within 6 months of the initial exit. This information will be collected during a telephone call with the patient and the referring physician.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Herault
-
Montpellier, Herault, Frankrike, 34295
- University Hospital of Montpellier
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion criteria:
- Patient over 18 years old
- Patient to whom an ADE is detected
- Possibility of carrying out a pharmaceutical consultation/interview
- Patient who has consented to participate
- Patient affiliated to the social welfare policy
- Patient who declared a referent medical doctor
Exclusion criteria:
- ADE linked to an emergency care activity
- Voluntary medical intoxication
- Impossibility of recovering the patient's drug history
- Under 18
- Pregnancy
- Participating in another category 1 interventional drug study
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Helsetjenesteforskning
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Ingen inngripen: Usual information transmission after ED admission
The emergency department (ED) sends to the referring doctor a letter to inform him about the reason of consultations in the emergency department (mail currently realized as part of the care process).
|
|
Eksperimentell: Optimized information transmission after ED admission
Sending to the community referring physician by the emergency department an discharge report containing the reason for emergency consultations (report currently made as part of the treatment).
Within 72 hours (working hours), the Emergency Clinical Pharmacist contacts the referring physician and the patient's community pharmacist to discuss how to manage the ADE.
In parallel, a second report, summary of the ADE (ADE-report), is sent to them.
The ADE-report, written and validated by the investigators (emergency physician and clinical pharmacist), includes the type of ADE, the suspected drug(s) and other recommendations: therapeutic modification, referral to specialized consultations (geriatrics ...).
|
Sending to the community referring physician by the emergency department an discharge report containing the reason for emergency consultations (report currently made as part of the treatment).
Within 72 hours (working hours), the Emergency Clinical Pharmacist contacts the referring physician and the patient's community pharmacist to discuss how to manage the ADE.
In parallel, a second report, summary of the ADE (ADE-report), is sent to them.
The ADE-report, written and validated by the investigators (emergency physician and clinical pharmacist), includes the type of ADE, the suspected drug(s) and other recommendations: therapeutic modification, referral to specialized consultations (geriatrics ...).
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Percentage of patients who had at least one readmission in the emergency department for the same reason
Tidsramme: within 6 month of the initial visit
|
within 6 month of the initial visit
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Percentage of patients who had at least one readmission in the emergency department for any reason
Tidsramme: within 6 month of the initial visit
|
within 6 month of the initial visit
|
Percentage of patients hospitalized for ADE at least once
Tidsramme: within 6 month of the initial visit
|
within 6 month of the initial visit
|
Percentage of patients hospitalized for any reason at least once
Tidsramme: within 6 months of the initial visit
|
within 6 months of the initial visit
|
Potentially avoidable hospitalization rate
Tidsramme: 6 months
|
6 months
|
Mortality rate related to ADE and all other causes
Tidsramme: 6 months
|
6 months
|
Number of medical consultations with a general community practitioner in connection with ADE and all causes combined
Tidsramme: 6 months
|
6 months
|
Number of medical consultations with a specialist community practitioner in connection with ADE and all causes combined
Tidsramme: 6 months
|
6 months
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Maxime VILLIET, PharmD, University Hospital, Montpellier
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- UF7591
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Bivirkningshendelse
-
Asceneuron S.A.RekrutteringDrug Drug InteractionNederland
-
Daewoong Pharmaceutical Co. LTD.RekrutteringDrug Drug InteractionKorea, Republikken
-
VistaGen Therapeutics, Inc.ParexelRekrutteringDrug Drug InteractionForente stater
-
CMP Development, LLCFullførtDrug Drug InteractionIndia
-
Shanghai Pharmaceuticals Holding Co., LtdFullført
-
Blade TherapeuticsFullført
-
Antios Therapeutics, IncFullførtDrug Drug InteractionCanada
-
KBP BiosciencesCovanceFullførtSunn | Drug Drug InteractionForente stater
-
University of Southern CaliforniaRekrutteringDrug Drug InteractionForente stater
-
Daewoong Pharmaceutical Co. LTD.Aktiv, ikke rekrutterendeDrug Drug InteractionKorea, Republikken
Kliniske studier på Optimized information transmission
-
Centre Hospitalier Universitaire, AmiensFullførtCerebral vaskulær lidelseFrankrike
-
Brigham and Women's HospitalAgency for Healthcare Research and Quality (AHRQ)RekrutteringGastrointestinale sykdommer | Hjertefeil | Infeksjoner | Urologiske sykdommer | Sjokk | Hematologiske sykdommer | Kritisk sykdom | Revmatiske sykdommer | Astma | Nyresvikt | Nevrologisk lidelse | KOLS-forverring | Hjertehendelse | Onkologisk problem | Arytmi | NyresykdomForente stater
-
Fox Chase Cancer CenterNational Cancer Institute (NCI)FullførtBrystkreft | Tykktarmskreft | Prostatakreft | ThoraxkreftForente stater
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...RekrutteringEsophagogastric Junction CarcinomaKina
-
59th Medical WingRekruttering
-
Surrey and Borders Partnership NHS Foundation TrustUniversity of SurreyAvsluttet
-
Brain SentinelNationwide Children's HospitalAvsluttet
-
Vidya RamanFullført
-
Population Health Research InstituteFullførtPasienter med risiko for tromboseCanada
-
Medtronic Cardiac Rhythm and Heart FailureFullførtHjertefeilForente stater, Storbritannia, Irland, Polen